Abstract:Platelets are anucleate blood cells that play key roles in thrombosis and hemostasis. Platelets are also effector cells in malignancy and are known to home into the microenvironment of cancers. As such, these cells provide central links between the hemostatic system, inflammation and cancer progression. Activation of platelets by cancers has been postulated to contribute to metastasis and progression of local tumor invasion. Similarly, cancer-activated platelets can increase the risk of development of both arterial and venous thrombosis; a major contributor to cancer-associated morbidity. Platelet granules secretion within the tumor environment or the plasma provide a rich source of potential biomarkers for prediction of thrombotic risk or tumor progression. In the case of myeloproliferative neoplasms (MPNs), which are characterized by clonal expansion of myeloid precursors and abnormal function and number of erythrocytes, leukocytes and platelets, patients suffer from thrombotic and hemorrhagic complications. The mechanisms driving this are likely multifactorial but remain poorly understood. Several mouse models developed to recapitulate MPN phenotype with one of the driving mutations, in JAK2 (JAK2V617F) or in calreticulin (CALR) or myeloproliferative leukemia virus oncogene receptor (MPL), have been studied for their thrombotic phenotype. Variability and discrepancies were identified within different disease models of MPN, emphasizing the complexity of increased risk of clotting and bleeding in these pathologies. Here, we review recent literature on the role of platelets in cancer-associated arterial and venous thrombosis and use MPN as case study to illustrate recent advances in experimental models of thrombosis in a malignant phenotype. We address major mechanisms of tumor-platelet communication leading to thrombosis and focus on the role of altered platelets in promoting thrombosis in MPN experimental models and patients with MPN. Recent identification of platelet-derived biomarkers of MPN-associated thrombosis is also reviewed, with potential therapeutic implications.

Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin

Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin

A role of platelet C-type lectin-like receptor-2 and its ligand podoplanin in vascular biology

Platelet-Leukocyte Interplay in Cancer Development and Progression

Platelets and cancer: a casual or causal relationship: revisited

Platelet (hem)itam Signaling Mediated Cancer-Associated Venous Thrombosis

Inhibition of Platelet Function: Does It Offer a Chance of Better Cancer Progression Control?

Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms

Cancer progression and tumor hypercoagulability: a platelet perspective

Blocking Podoplanin Inhibits Platelet Activation and Decreases Cancer-Associated Venous Thrombosis.

Interaction Between Circulating Cancer Cells and Platelets: Clinical Implication

Consequences of platelet-educated cancer cells on the expression of inflammatory and metastatic glycoproteins

The dynamic role of platelets in cancer progression and their therapeutic implications

Platelets and circulating (tumor) cells: partners in promoting metastatic cancer

The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis

C-type lectin-like receptor 2: roles and drug target

A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis

Role of platelets in inflammation and cancer: novel therapeutic strategies

Role of platelets and platelet receptors in cancer metastasis

Venous thrombosis and cancer: from mouse models to clinical trials

Podoplanin: A Potential Therapeutic Target for Thrombotic Diseases